ArticleGastro hep advances2026
CD163 Expression Protects Against Early Hepatic Steatosis in Western Diet-Fed Male Mice.
Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Extracellular Vesicle Surface Protein Profiling in Metabolic Dysfunction-associated Steatotic Liver Disease in Obesity.Journal of extracellular biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Sustained and excessive consumption of dietary lipids and sugars can lead to hepatic steatosis triggering metabolic dysfunction-associated steatohepatitis (MASH) characterized by inflammation and hepatocellular damage. The activation of macrophages is suggested to play an important role in the pathogenesis of MASH. Liver macrophages have a high expression of the macrophage-specific scavenger receptor CD163, but during MASH development CD163 undergoes increased shedding and downregulated expression in the liver. In this study, we investigate the relation between the expression of CD163 and early hepatic steatosis in mice. Methods: The time-dependent relation between steatosis and CD163 expression was evaluated by staining of liver specimens from male mice after 0, 5, 15, or 25 weeks of Western diet (WD) feeding. To evaluate the impact of CD163 on the early development of hepatic steatosis, we compared CD163 knockout mice and wild-type littermates fed on WD or chow diet for 8 weeks. Besides staining of liver specimens, plasma cytokines were measured, the transcriptome was analyzed by bulk RNA sequencing and liver macrophages were evaluated by flow cytometry. Results: CD163 expression decreased in parallel to the development of hepatic steatosis in WD-fed mice. WD-fed CD163 knockout mice developed more pronounced hepatic steatosis compared to CD163 wild-type littermates after 8 weeks; however, the number of macrophages, systemic cytokine levels, and transcriptome were unaffected by the genotype. Conclusion: A protective role (direct or indirect) of CD163 on early development of hepatic steatosis was indicated by the finding that the severity of steatosis was significantly stronger in CD163 knockout mice. Furthermore, it underlines the importance of macrophages in lipid-driven liver disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.